Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

Janet H. Ford¹ · Virginia L. Stauffer¹ · Peter McAllister² · Sreelatha Akkala³ · Matthew Sexson¹ · David W. Ayer¹ · Shufang Wang¹

Published online: 18 December 2020
© The Author(s) 2020

Correction to: Quality of Life Research
<https://doi.org/10.1007/s11136-020-02632-0>

In the original publication, Fig. 3 showed an upward directed arrow for improvement in the monthly migraine headache days. However, the direction of the arrow has been corrected to downward direction, to present the improvement in monthly migraine headache days.

The error was limited to Fig. 3 only, and the revised Fig. 3 is shared in this correction.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s11136-020-02632-0>.

✉ Janet H. Ford
ford_janet@lilly.com

¹ Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN 46225, USA

² New England Institute for Neurology and Headache, Stamford, USA

³ Eli Lilly Services India Pvt Ltd, Bengaluru, India

Fig. 3 Mean changes from baseline in monthly migraine headache days during treatment and post-treatment phase. * $p < 0.05$ for GMB 240 mg vs 120 mg. *BL* baseline, *GMB* galcanezumab, *LS* least squares, *SE* standard error

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.